Jan 16, 2024, 7:43 am EST
Share
Reprints
In this article
The European pharmaceutical sector looks set for a good year on strong cash flows and attractive valuations, according to UBS analysts. They picked out four stocks that could particularly benefit but left out weight-loss drug pioneer and market darling Novo Nordisk, and struck a bearish note on AstraZeneca.
Continue reading this article with a Barron’s subscription.
Signup bonus from
